Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data.
RAPNO
interobserver agreement
objective response
overall survival
progression-free survival
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
14 10 2020
14 10 2020
Historique:
pubmed:
28
3
2020
medline:
29
4
2021
entrez:
28
3
2020
Statut:
ppublish
Résumé
Although the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group has made recommendations for response assessment in patients with medulloblastoma (MBL) and leptomeningeal seeding tumors, these criteria have yet to be evaluated. We examined MR imaging and clinical data in a multicenter retrospective cohort of 269 patients with MBL diagnoses, high grade glioma, embryonal tumor, germ cell tumor, or choroid plexus papilloma. Interobserver agreement, objective response (OR) rates, and progression-free survival (PFS) were calculated. Landmark analyses were performed for OR and progression status at 0.5, 1.0, and 1.5 years after treatment initiation. Cox proportional hazards models were used to determine the associations between OR and progression with overall survival (OS). Subgroup analyses based on tumor subgroup and treatment modality were performed. The median follow-up time was 4.0 years. In all patients, the OR rate was .0.565 (95% CI: 0.505-0.625) by RAPNO. The interobserver agreement of OR determination between 2 raters (a neuroradiologist and a neuro-oncologist) for the RAPNO criteria in all patients was 83.8% (k statistic = 0.815; P < 0.001). At 0.5-, 1.0-, and 1.5-year landmarks, both OR status and PFS determined by RAPNO were predictive of OS (hazard ratios [HRs] for 1-year landmark: OR HR = 0.079, P < 0.001; PFS HR = 10.192, P < 0.001). In subgroup analysis, OR status and PFS were predictive of OS for all tumor subtypes and treatment modalities. RAPNO criteria showed excellent consistency in the treatment response evaluation of MBL and other leptomeningeal seeding tumors. OR and PFS determined by RAPNO criteria correlated with OS.
Sections du résumé
BACKGROUND
Although the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group has made recommendations for response assessment in patients with medulloblastoma (MBL) and leptomeningeal seeding tumors, these criteria have yet to be evaluated.
METHODS
We examined MR imaging and clinical data in a multicenter retrospective cohort of 269 patients with MBL diagnoses, high grade glioma, embryonal tumor, germ cell tumor, or choroid plexus papilloma. Interobserver agreement, objective response (OR) rates, and progression-free survival (PFS) were calculated. Landmark analyses were performed for OR and progression status at 0.5, 1.0, and 1.5 years after treatment initiation. Cox proportional hazards models were used to determine the associations between OR and progression with overall survival (OS). Subgroup analyses based on tumor subgroup and treatment modality were performed.
RESULTS
The median follow-up time was 4.0 years. In all patients, the OR rate was .0.565 (95% CI: 0.505-0.625) by RAPNO. The interobserver agreement of OR determination between 2 raters (a neuroradiologist and a neuro-oncologist) for the RAPNO criteria in all patients was 83.8% (k statistic = 0.815; P < 0.001). At 0.5-, 1.0-, and 1.5-year landmarks, both OR status and PFS determined by RAPNO were predictive of OS (hazard ratios [HRs] for 1-year landmark: OR HR = 0.079, P < 0.001; PFS HR = 10.192, P < 0.001). In subgroup analysis, OR status and PFS were predictive of OS for all tumor subtypes and treatment modalities.
CONCLUSION
RAPNO criteria showed excellent consistency in the treatment response evaluation of MBL and other leptomeningeal seeding tumors. OR and PFS determined by RAPNO criteria correlated with OS.
Identifiants
pubmed: 32215549
pii: 5811685
doi: 10.1093/neuonc/noaa072
pmc: PMC7566367
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1536-1544Subventions
Organisme : NCI NIH HHS
ID : F30 CA239407
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB015896
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA235002
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB001680
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cell. 2018 May 31;173(6):1549
pubmed: 29856958
AJNR Am J Neuroradiol. 2012 Mar;33(3):550-5
pubmed: 22173760
Klin Padiatr. 2004 Nov-Dec;216(6):331-42
pubmed: 15565548
Neurotherapeutics. 2009 Jul;6(3):570-86
pubmed: 19560746
J Clin Oncol. 2013 Aug 10;31(23):2927-35
pubmed: 23835706
Nature. 2016 Jan 21;529(7586):351-7
pubmed: 26760213
NCHS Data Brief. 2016 Sep;(257):1-8
pubmed: 27648773
Lancet Oncol. 2010 Sep;11(9):871-9
pubmed: 20598636
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
J Clin Oncol. 2002 Oct 15;20(20):4209-16
pubmed: 12377964
Lancet Oncol. 2013 Nov;14(12):1200-7
pubmed: 24140199
Neuro Oncol. 2018 Jan 10;20(1):13-23
pubmed: 28449033
Clin Cancer Res. 2016 Feb 1;22(3):575-81
pubmed: 26490307
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
J Child Neurol. 2016 Oct;31(12):1341-53
pubmed: 26336203
Pediatr Blood Cancer. 2013 Sep;60(9):1397-401
pubmed: 23625747
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
Neuro Oncol. 2017 Apr 1;19(4):484-492
pubmed: 28039364
Childs Nerv Syst. 2013 Oct;29(10):1871-81
pubmed: 23811803
J Neurosurg. 1997 May;86(5):747-54
pubmed: 9126887